| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Biocryst Pharmaceuticals Inc (BCRX) has 10 insiders with recent SEC Form 4 filings, including 13 buys and 5 sells. BCRX is classified in the Pharmaceuticals industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Dir | 1.32M | $12.32M | - | |
| Pres | 902.6K | $8.39M | - | |
| Other | 398.8K | $3.71M | - | |
| CFO | 268.7K | $2.50M | - | |
| Dir | 93.2K | $866.7K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Aug 12, 2016 | Staab Thomas R II | Senior Vice President And CFO | Sell | 5,864 | $5.18 | $30,388.06 | -2.3% | |
| Aug 9, 2016 | Staab Thomas R II | Senior Vice President And CFO | Sell | 14,577 | $4.43 | $64,576.11 | -10.1% | |
| Feb 5, 2016 | Baker Bros. Advisors LP59 | 10% Owner | Buy | 45,000 | $6.33 | $284,656.50 | +0.4% | |
| Feb 4, 2016 | Baker Bros. Advisors LP59 | 10% Owner | Buy | 207,715 | $6.43 | $1,336,586.04 | +0.5% | |
| Jan 28, 2016 | Baker Bros. Advisors LP59 | 10% Owner | Buy | 88,345 | $6.95 | $613,985.73 | +0.4% | |
| Jan 22, 2016 | Baker Bros. Advisors LP59 | 10% Owner | Buy | 106,800 | $7.28 | $777,757.44 | +0.4% | |
| Jan 20, 2016 | Baker Bros. Advisors LP59 | 10% Owner | Buy | 344,895 | $7.28 | $2,510,143.35 | +0.6% | |
| Dec 21, 2015 | Staab Thomas R II | Senior Vice President And CFO | Sell | 3,052 | $10.86 | $33,144.72 | -2.2% | |
| Dec 17, 2015 | Staab Thomas R II | Senior Vice President And CFO | Sell | 3,000 | $10.49 | $31,470.00 | -2.1% |